Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.42 |
| ▸ | CES2 | O00748 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1478038 | 0.80 | ALDH1A1 (0.43) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL262234 | 0.76 | CES2 (0.43) | CES1CES2ALDH1A1TSHRDAO | |
| SCHEMBL29014581 | 0.76 | CES1 (0.39) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL262233 | 0.76 | CES2 (0.43) | CES1CES2ALDH1A1TSHRDAO | |
| SCHEMBL4713673 | 0.76 | RECQL (0.46) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL6801638 | 0.76 | CES2 (0.43) | CES1CES2ALDH1A1TSHRDAO | |
| SCHEMBL7607185 | 0.76 | CES1 (0.39) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL2343352 | 0.75 | PDE4A (0.47) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL2343354 | 0.75 | PDE4A (0.47) | NFE2L2CA2CA12CA1CA9 | |
| SCHEMBL6319759 | 0.73 | CES2 (0.52) | CES1CES2ALDH1A1TSHRDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3278110-A1 | LIGAND INDUCIBLE POLYPEPTIDE COUPLER SYSTEM | Intrexon Corporation (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016160791-A1 | LIGAND INDUCIBLE POLYPEPTIDE COUPLER SYSTEM | INTREXON CORPORATION (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20090202472-A1 | MOLECULES AND CHIMERIC MOLECULES THEREOF | APOLLO LIFE SCIENCES LIMITED (AU) | 2009-08-13 | — | — | US | disclosed |
| US-20090175819-A1 | MOLECULE AND CHIMERIC MOLECULES THEREOF | APOLLO LIFE SCIENCES LIMITED (AU) | 2009-07-09 | — | — | US | disclosed |
| EP-1848738-A1 | PARAMETER SELECTED GM-CSF, IL-3, IL-4, IL-5 AND CHIMERAS THEREOF FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES | Apollo Life Sciences Limited (AU) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006079169-A1 | PARAMETER SELECTED GM-CSF, IL-3, IL-4, IL-5 AND CHIMERAS THEREOF FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES | APOLLO LIFE SCIENCES LIMITED (AU) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175819-A1 | MOLECULE AND CHIMERIC MOLECULES THEREOF | IL2RA, IFNAR1, IL2 | NFE2L2 2033/4885CA2 2519/4885CA12 587/4885 |
| US-20090202472-A1 | MOLECULES AND CHIMERIC MOLECULES THEREOF | IL2RA, IL2, IL15RA | NFE2L2 913/4885CA2 1612/4885CA12 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.